NC410 is a first-in-class immunomedicine designed to block immune suppression mediated by LAIR-1, an immunomodulatory receptor expressed on a variety of immune cells including T cells and myeloid cells. In non-clinical models and early-stage monotherapy clinical studies, we have demonstrated that NC410 can remodel collagen in the extracellular matrix (ECM), the tissue matrix surrounding the tumor, which enhances T cell infiltration into the tumor. Elevated collagen levels in the ECM are associated with resistance to PD-1 and PD-L1 therapies. Our translational work has shown that NC410 blocks the interaction of LAIR-1 with its binding partners, thereby promoting T cell function and immune cell mediated activity to contribute to restoring anti-tumor activity. Consistent with our strategy, we believe NC410 has the potential to address the needs of patients who are not adequately addressed by currently available therapies.

LNCB74 is an antibody-drug conjugate that binds specifically to B7-H4, a validated target on tumors.  B7-H4 protein is expressed on multiple tumor types, including many cancers specific to women (breast, ovarian and endometrial). LNCB74 has been specifically designed to reduce toxicity while improving tumor killing.  Our research showed LNCB74 has potent antitumor activity in CDX and PDX models.

Programs Available for Partnering

 

NC525, is a monoclonal antibody and specifically binds to LAIR-1 to induce killing of AML blast cells and leukemic stem cells while sparing normal blood cells, including hematopoietic stem cells.  The mechanism was recently described and published in the Journal of Clinical Investigation (Lovewell RR et al., J Clin Invest 2023).  Our research further showed that NC525 reduced tumor burden in leukemia models.

NC605 is a monoclonal antibody and specifically binds to S15.  S15 is expressed on osteoclasts, a cell-type in bone that breaks down old and damaged bone.  NC605 has been specifically designed to inhibit osteoclasts and prevent bone loss.  In addition, it has the added benefit of promoting bone formation.  It is being developed for osteogenesis imperfecta, a rare bone disease where patients suffer from weak and brittle bones, and other bone disorders such as non-union fractures and osteoarthritis.

NC181 is a monoclonal antibody and specifically binds to APOE4.  APOE4 is major risk factor for Alzheimer’s disease.  NC181 has been designed to reduce amyloid plaques, suppress neuroinflammation and improve blood flow in the brain.

 NextCure Expanded Access Policy can be viewed here.